Lyon, April 26, 2024
– Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, publishes the number of shares making up its capital and the total number of voting rights (articles L. 233-8 II of the commercial code and 223-16 of the general regulations of the AMF) as of March 31, 2024.
|
Date |
Number of shares making up the share capital |
Total number of theoretical voting rights* |
|
March 31, 2024 |
7,845,124 |
8,817,339 |
* The theoretical voting right is calculated in accordance with article 223-11 of the General Regulations of the AMF (Financial Markets Authority), on the basis of all the shares to which voting rights are attached, including the shares deprived of voting rights.
About Theranexus
Theranexus is an innovative biopharmaceutical company, spun out from the CEA and specialized in the treatment of rare neurological diseases. The Company has a unique platform for identifying and characterizing innovative therapy drug candidates in the field of rare neurological disorders and a first drug candidate in clinical development in Batten disease.
THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
yGycaJ1pamnGl2ucaJ1qb5Zobm1kkpKdbGOXmGNxl8mdbW1jl5lkaZTKZnFmmG5m
– To control this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/85390-theranexus_cp_ddv-26042024.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com